Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIAXI: NT 201 in Chronic Troublesome Sialorrhea
NCT02091739Phase 3Completed
- Sponsor
- Merz
- Start
- Apr 2014
- Primary completion
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of incobotulinumtoxinA in sialorrhea (3 arms), sponsored by Merz. Primary endpoints: Unstimulated Salivary Flow Rate at 4 weeks and Global Impression of Change Scale at 4 weeks. Started Apr 2014; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
sialorrhea
Beyond the preview
Go deeper on NCT02091739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091739.